Achaogen Inc : LifeSci Capital Initiates Coverage of Achaogen

Developing Potent Antibiotics to Treat Serious Multi-Drug Resistant Infections

Report Available here: www.lifescicapital.com/equity-research/achaogen/

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Achaogen (NasdaqGM: AKAO), a biotechnology company developing novel antibiotics to combat the rise of bacterial resistance. Achaogen's lead product candidate is plazomicin, a potent antibiotic with activity against a broad range of serious gram negative, multi-drug resistant (MDR) pathogens.

Plazomicin has been designed with two key chemical modifications to overcome most known mechanisms of resistance to aminoglycosides. The Centers for Disease Control and Prevention (CDC) consider resistance to this antibiotic class, an important last-line of defense against multidrug-resistant (MDR) pathogens, to be one of the most pressing public health threats. Carbapenem-resistant Enterobacteriaceae (CRE) are resistant to most commercially available drugs and are associated with particularly high mortality rates. Achaogen expects to report data from two Phase III trials in the first half of 2017, which could position the Company to file an NDA for plazomicin in the second half of 2017.

In a 35 page Initiation Report, LifeSci Capital explains the Company's development strategy, the landscape of existing therapies, and the favorable shift in regulatory and economic environment that now support development in the antibiotic space.

Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Achaogen as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.

Analyst Contact:

SOURCE: LifeSci Capital, LLC